ANTH Related Analyst Ratings

Mar 5, 2013 07:01 AM Jefferies Starts Anthera Pharma (ANTH) at Buy, $2 PT

Nov 13, 2012 10:12 AM Leerink Swann Resumes Anthera Pharma (ANTH) at Outperform

Jul 9, 2012 09:10 AM Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); B-Mod Still Has A Shot

Jun 29, 2012 07:00 AM Citi Downgrades Anthera Pharma (ANTH) to Sell

Jun 29, 2012 06:59 AM Human Genome (HGSI) Could Get 15% More in Takeover Bid - Analyst

Jun 28, 2012 07:41 AM JMP Securities Downgrades Anthera Pharma (ANTH) to Market Perform

Jun 13, 2012 07:24 AM JMP Securities Starts Anthera Pharma (ANTH) at Market Outperform

May 7, 2012 09:07 AM Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); All Eyes on June Phase 2 Data

Apr 19, 2012 08:06 AM Glaxo's Bid for Human Genome Is a Positive for Anthera Pharma (ANTH) - Analyst

Mar 29, 2012 08:40 AM Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Expectations for June Phase 2 PEARL Trial

Mar 19, 2012 08:51 AM Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Looking Ahead to Other B-Mod Programs

Mar 12, 2012 09:11 AM Cowen Downgrades Anthera Pharma (ANTH) to Neutral

Mar 12, 2012 08:36 AM Canaccord Genuity Maintains a 'Buy' on Anthera Pharma (ANTH); Hard Stop to Varespledib/A001 Development

Mar 12, 2012 07:42 AM Citi Downgrades Anthera Pharma (ANTH) to Neutral

Mar 2, 2012 02:31 PM Summer Street Starts Anthera Pharma (ANTH) at Buy, $15 Price Target

Feb 22, 2012 10:11 AM Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); ISTA, PEARL Interims Expected Mid-to-late March

Feb 21, 2012 08:45 AM Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); VISTA-16 Interim Color Looms as CV Becomes Investor Focus

Jan 17, 2012 10:29 AM Canaccord Genuity on Biotechnology: 2012 Best Ideas - Aegerion (AEGR), Anthera (ANTH): A Year of Transformative, Yet Derisked Late-Stage Binary Catalysts

Jan 10, 2012 08:47 AM Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Panel Takeaways: VISTA Interim Likely to Miss, but to Yield Blended Event Rate

Jan 4, 2012 09:09 AM Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Vista Interim Look: Tough Hurdle, But Think Final Data Will Be Positive

Dec 8, 2011 09:16 AM UPDATE - Canaccord Genuity Initiates Coverage on Anthera Pharma (ANTH) at Buy; Two Shots on Phase 3 Goal

Dec 8, 2011 07:53 AM Canaccord Genuity Starts Anthera Pharma (ANTH) at Buy with $13 Price Target

Dec 2, 2011 07:44 AM Wedbush Upgrades Anthera Pharma (ANTH) to Outperform; PEARL-SC Interim Analysis Shows B-Cell Reduction

Dec 2, 2011 07:13 AM Collins Stewart Starts Anthera Pharma (ANTH) at Buy; Rare Risk/Reward Opportunity

Nov 1, 2011 06:56 AM Deutsche Bank Starts Anthera Pharma (ANTH) at Buy; Risk/Reward Into VISTA-16 is Favorable

Sep 19, 2011 08:25 AM Citi Starts Anthera Pharma (ANTH) at Buy

Aug 1, 2011 08:49 AM Wedbush Downgrades Anthera Pharma (ANTH) to Neutral; Continued Progress in Clinical Trials is Encouraging but Valuation Suggests Limited NT Upside

May 17, 2011 07:56 AM Leerink Swann Starts Anthera Pharma (ANTH) at Outperform; Compelling Risk-Reward with Advanced Programs in SLE and ACS

Oct 6, 2010 12:46 PM Wedbush Starts Anthera Pharma (ANTH) at Outperform, $8 Price Target

Apr 23, 2010 09:40 AM Cowen & Co Initiates Coverage on Anthera Pharmaceuticals (ANTH) with an Outperform